Navigation Links
Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
Date:10/3/2007

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at BIO InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 a.m. PDT (2:45 p.m. EDT). The conference is being held at The Palace Hotel in San Francisco.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. will present an overview of Anadys and an update on its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived until October 24, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop and commercialize novel small molecule medicines for the treatment of HCV and cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and Anadys' Form 10-Q for the quarter ended June 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, ... to accept new patients in need of skilled pediatric dentistry in Rock ... Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... core lab with extensive therapeutic experience and operational excellence in oncology clinical trials, ... clinical trial for the treatment of non-small cell lung cancer and small cell ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... planning, and related services to communities across eastern Texas, is announcing a charity ... providing meals to hungry children and adults. , Consistently a top-rated nonprofit ...
(Date:3/22/2017)... ... ... Chris Humphrey Insurance Agency, a North Carolina firm offering asset protection services and ... initiating a charity event to raise support for five year old Dillyn, a young ... Friday evening in September 2014. At the time, Dillyn was only four years old, ...
(Date:3/22/2017)... ... March 22, 2017 , ... HumanHaus is proud to announce the launch ... broom was great when it was invented, but our customers today are busy, energetic, ... social young couple, the empty nesters and retired that want to travel. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... TapImmune, Inc. (NASDAQ: TPIV), ... of innovative peptide and gene-based immunotherapeutics for the ... that it will participate in two upcoming Investor ... Wilson , Chairman and CEO of TapImmune, will ... pipeline and partnering opportunities for its proprietary PolyStart ...
(Date:3/22/2017)... , March 22, 2017 Hologic, Inc. ... has completed the acquisition of Cynosure, Inc., a leader ... share in cash. "We are pleased to ... working with Michael Davin and the entire ... large, rapidly growing medical aesthetics market," said Steve ...
(Date:3/22/2017)... 2017 TFS is pleased to announce the ... Tumaian , two global executive positions in Medical Affairs and Clinical ... Leadership Team and will report to Dr. Montse Barceló , ... ... 10 years of medical and scientific expertise gained across leading biopharmaceutical ...
Breaking Medicine Technology: